Journal for ImmunoTherapy of Cancer
IF
13.75
Papers
5,160
Papers 4,987
1 page of 499 pages (4,987 results)
Newest
Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis.
Source
Source
Source
#1Carlo BifulcoH-Index: 7
#2Jon M. RichardsH-Index: 33
Last. Yiwei Zhang (MSD: MSD)
view all 12 authors...
Background null Intratumoral administration of V937, a bioselected genetically unmodified Coxsackievirus A21, has shown antitumor activity both as a monotherapy and in combination with the anti–PD-1 antibody pembrolizumab.1–3 V937 induces lytic tumor cell infection and upregulation of members of immune checkpoint pathways.2 We present the results from the phase 1b MITCI study that evaluated V937 plus ipilimumab for advanced melanoma. null Methods null Eligible patients had unresectable or metast...
Source
Source
Source
#1Aung Naing (The University of Texas MD Anderson Cancer Center)H-Index: 60
#2Margaret K. Callahan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 56
Last. Umut Y. UlgeH-Index: 6
view all 11 authors...
Background null NL-201 is a selective and long-acting computationally designed alpha-independent agonist of the IL-2 and IL-15 receptors, which share beta and gamma signaling subunits. NL-201 is being developed as a potent activator of CD8+ T cells and NK cells for cancer immunotherapy. Binding to the beta and gamma subunits selectively stimulates dose-dependent expansion and tumor infiltration of cytotoxic CD8+ T cells and NK cells, thereby enhancing the immune response in the tumor. The absenc...
Source
Source
#1Jonathan H. ChenH-Index: 22
#1Jonathan H. ChenH-Index: 18
Last. Nir HacohenH-Index: 90
view all 10 authors...
Source
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.